Well Xtrac and Skin Care sales in 2008 was 29m, in 2007 25.8m and in 2006 20.4m
In recent years this division sales started to decline but are now back to above the 2009 levels.
2008 and 2009 U.S. was at the peak of the Financial Crises, yet ... this business was still valued at at $22.7m, $32.1m respectively.
The very same business was valued in 2007 at $60.6 USD (EV) ... on a total revenue of $31m (of which XTRAC and Skin generated 25.8)
Gross Profits were at around $17m usd . The company / very same business we are talking about ... was valued at the following EV/Gross Profits Ratio of:
Mow, over the past 12 months (2014) this division generated Gross Profits amounting to $21m (about 20% higher than the gross profits made in 2008).
Even if u take the multiple used by market during the worst Market Crisis since the greatest depression, you should value it at at least $27.305m.
The Economy is currently not in a Credit Crunch .. and XTRAC is finally growing at high rates (YoY) ... ... so, the 2008 implied $27.30m represents an unlikely low valuation scenario.
You can choose the multiple u want to use ... but ... be honest with yourself and do not make your Short Bias affect/dictate your Choice.
What do you think? ... does it make sense?
So, what is the valuation your Valuation of the XTRAC?
PHMD disclosed Xtrac and Neovax as one business segment, labeled physician Recurring.
this Segment generated 34.24m in sales in 2014 up from 21.28m in sales in 2013.
Isn't this an impressive growth rate?
This will probably be trading at 2.50 before the results. Then, if results are bad it will be trading at 1.00 if good ... at 5.
No one here can predict the outcome of the PhII ... this is pure gambling
Someone just went long 1391 ATHX 3.0USD PUTS expiring 05/15/2015.
Breaking even only if ATHX traded below 2.00 by the expiration date.
Worldwide there are 48 listed companies mentioning "stem cell" in their business description.
Total Market Cap of all the 48 listed Companies = 11.72b USD
Total revenue generated by the 48 listed Companies = 1.37b USD
valuing an entire industry at 11.72b USD? ... If you are really investing in the STEM CELL revolution you buy a basked of companies ... not only ATHX.
Thank you, finally someone that is not all about pumping ATHX. Maybe you could also answer some more questions about ATHX:
On the clinicaltrials gov page, there are 7 ATHX studies for Multistem.
3 have been completed so far:
UC Phase II trial - Completed - did not reach the Primary Endpoints.
I do wonder what did happen to the other 2 completed studies.
1. Safety Study of AMI MultiStem® to Treat Heart Attacks
Phase 1 completed at around May 2012. Is this still in development? 3 years have gone by. Was this the base of the Clinical Trial soon to begin: "A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction"?
Why did the company wait 3 years
2. Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
Phase 1 was completed on Around January 2012. Is this program still in development? Why no developements in over 3 years?
In the last 10k the company is still stating: |We are preparing to advance our GvHD program into the next phase of clinical development and have had several interactions with the United States Food and Drug Administration, or FDA, |
APRIL 28, 2014:
+ ATHR communicates that "MultiStem Demonstrates Good Tolerability and Safety Profile But Fails to Show
Efficacy Over 8 Weeks in Patients With Chronic, Advanced Ulcerative Colitis"
+ Price Per hares Dropped by 51.28% on the news.
+ ATHX informed investors that "Additional 16-week results, including data about the impact from a second round of dosing for a subset of patients, longer term secondary clinical endpoints, and biomarker evaluation will be available after additional analysis has been completed"
MAY 08, 2014:
+ ATHX reports First Quarter 2014 Results and commented on ATHX, promising additional data: "Additional evaluations are forthcoming, includingdata about the impact from a second round of dosing for a subset of patientsand longer-term secondary efficacy endpoints at 16 weeks, as well as biomarker analysis."
SINCE MAY 08, 2014 ... ATHX completely stopped to talk about the Additional 16-week Results ... ... The 16 week DATA (TO MY KNOWLEDGE) HAVE NEVER BEEN RELEASED.
Ignoring the problem?
When athx announced the UC trial failure it also stated it was collecting the 16 wk data ... and expected to release them in the near future.
Well, one year has gone by .... and I still can not find the data.
Why is athx not disclosing it? Really way worse than expected ... hoped for?
1 year ago, athx promised to release the 16 wk data of the uc trial.
Where is the data? As u can see athx is not to be trusted.
So, pumpers, tell me where the data is .why are u not talking about it?
In order to be able to build a short position at higher prices ahead of phII failure announcement?
It is hilarious how pumpers on 5 his board manipulate the truth. If u write a critical comment you are immediately labeled as a basher .... if u say something bull .
this pumping strategy is peculiar of a group called the dress team. This IR firm is in the business of pumping stocks for compensation. Looks like they have been at work here ... judging from the strategy applied by boll posters on this board.
Price run up on positive pumping comments.
PII Results came out .. and it went down 69% in pre market.
Would you give a lot Price target to a client of yours that makes you millions a year.
2013 Maxim was the lead Manager on ATHX offering of 10m shares at 2usd
2014 Maxim was the lead Manager on ATHX offering of 5m shares at 4.10.
Maxim sold Clients/people ATHX Shares at 4.10 in 2014 ... are you expecting Maxim to put a Price target lowe than that? lol